These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 17595753)

  • 1. Raloxifene and selective cell cycle specific agents: a case for the inclusion of raloxifene in current breast cancer treatment therapies.
    Fryar-Tita EB; Das JR; Davis JH; Desoto JA; Green S; Southerland WM; Bowen D
    Anticancer Res; 2007; 27(3B):1393-9. PubMed ID: 17595753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The protection against trimetrexate cytotoxicity in human bone marrow by sequence-dependent administration of raloxifene, 5-fluorouracil/trimetrexate.
    Das JR; Fryar EB; Green S; Southerland WM; Bowen D
    Anticancer Res; 2006; 26(6B):4279-86. PubMed ID: 17201145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Raloxifene attenuation of 5-FU/methotrexate cytotoxicity in human breast cancer cells: the importance of sequence in combination chemotherapy.
    Fryar EB; Das JR; Davis JH; Desoto JA; Laniyan I; Southerland WM; Bowen D
    Anticancer Res; 2006; 26(3A):1861-7. PubMed ID: 16827118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Raloxifene attenuation of methotrexate cytotoxicity in human bone marrow by sequence-dependent administration of raloxifene, 5-FU/methotrexate.
    Das JR; Fryar EB; Epie NN; Southerland WM; Bowen D
    Anticancer Res; 2006; 26(3A):1877-83. PubMed ID: 16827120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequence-dependent administration of raloxifene and 5-fluorouracil/pemetrexed protects against pemetrexed cytotoxicity in human bone marrow.
    Das JR; Fryar-Tita EB; Green S; Southerland WM; Bowen D
    Anticancer Res; 2007; 27(2):825-33. PubMed ID: 17465208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sequence- and time-dependent antagonism between raloxifene and methotrexate in human breast cancer cells.
    De Soto JA; Bowen D; Davis JH; Southerland WM; Hawkins M
    Anticancer Res; 2002; 22(2A):1007-9. PubMed ID: 12014617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequence-dependent administration of 5-fluorouracil maintains methotrexate antineoplastic activity in human estrogen-negative breast cancer and protects against methotrexate cytotoxicity in human bone marrow.
    Das JR; Fryar-Tita EB; Zhou Y; Green S; Southerland WM; Bowen D
    Anticancer Res; 2007; 27(6B):3791-9. PubMed ID: 18225534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequential combination chemotherapy in human breast cancer: a basis for increased antineoplastic activity and bone marrow protection.
    Davis JH; Desoto JA; Fryar EB; Southerland WM; Bowen D
    Cell Mol Biol (Noisy-le-grand); 2007 May; 53(3):18-26. PubMed ID: 17531145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implications for improved high-dose methotrexate therapeutic effects in cultured human breast cancer and bone marrow cells.
    Bowen D; Southerland WM; Johnson DH; Hawkins M; Hughes DE
    Cancer Detect Prev; 2000; 24(5):452-8. PubMed ID: 11129987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selectivity in human breast cancer and human bone marrow using trimetrexate in combination with 5-fluorouracil.
    Bowen D; Johnson DH; Southerland WM; Hughes DE; Hawkins M
    Anticancer Res; 1999; 19(5B):3837-40. PubMed ID: 10628320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The combination of raloxifene and epigallocatechin gallate suppresses growth and induces apoptosis in MDA-MB-231 cells.
    Stuart EC; Rosengren RJ
    Life Sci; 2008 Apr; 82(17-18):943-8. PubMed ID: 18371987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effects of estrogen and selective estrogen receptor modulators on osteoporosis].
    Urano T
    Clin Calcium; 2005 Apr; 15(4):591-5. PubMed ID: 15802770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Evidence for the selective estrogen receptor modulator raloxifene: its evolving role in the treatment of osteoporosis].
    Ohta H
    Clin Calcium; 2008 Oct; 18(10):1442-50. PubMed ID: 18830041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 5-Fluorouracil simultaneously maintains methotrexate antineoplastic activity in human breast cancer and protects against methotrexate cytotoxicity in human bone marrow.
    Bowen D; Johnson DH; Southerland WM; Hughes DE; Hawkins M
    Anticancer Res; 1999; 19(2A):985-8. PubMed ID: 10368642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between bone mass, invasive breast cancer incidence and raloxifene therapy in postmenopausal women with low bone mass or osteoporosis.
    Burshell AL; Song J; Dowsett SA; Mershon JL; Delmas PD; Secrest RJ; Cauley JA
    Curr Med Res Opin; 2008 Mar; 24(3):807-13. PubMed ID: 18254988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Raloxifene use in clinical practice: efficacy and safety.
    Goldstein SR; Duvernoy CS; Calaf J; Adachi JD; Mershon JL; Dowsett SA; Agnusdei D; Stuenkel CA
    Menopause; 2009; 16(2):413-21. PubMed ID: 19092711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of retinoblastoma tumor suppressor protein makes human breast cancer cells more sensitive to antimetabolite exposure.
    Derenzini M; Donati G; Mazzini G; Montanaro L; Vici M; Ceccarelli C; Santini D; Taffurelli M; Treré D
    Clin Cancer Res; 2008 Apr; 14(7):2199-209. PubMed ID: 18381962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The optimal schedule for 5-fluorouracil radiosensitization in colon cancer cell lines.
    Ojima E; Inoue Y; Watanabe H; Hiro J; Toiyama Y; Miki C; Kusunoki M
    Oncol Rep; 2006 Nov; 16(5):1085-91. PubMed ID: 17016597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concentration-dependent effects of a selective estrogen receptor modulator raloxifene on proliferation and apoptosis in human uterine leiomyoma cells cultured in vitro.
    Liu J; Matsuo H; Xu Q; Chen W; Wang J; Maruo T
    Hum Reprod; 2007 May; 22(5):1253-9. PubMed ID: 17220163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pretreatment with 5-FU enhances cisplatin cytotoxicity in head and neck squamous cell carcinoma cells.
    Ijichi K; Adachi M; Hasegawa Y; Ogawa T; Nakamura H; Kudoh A; Yasui Y; Murakami S; Ishizaki K
    Cancer Chemother Pharmacol; 2008 Oct; 62(5):745-52. PubMed ID: 18075740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.